Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/179950
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jimenez Fonseca, Paula | - |
dc.contributor.author | Carmona Bayonas, Alberto | - |
dc.contributor.author | Martínez Torron, Alba | - |
dc.contributor.author | Alsina, Maria | - |
dc.contributor.author | Custodio, Ana | - |
dc.contributor.author | Serra, Olbia | - |
dc.contributor.author | Cacho Lavín, Diego | - |
dc.contributor.author | Limon Miron, Maria Luisa | - |
dc.contributor.author | Sauri, Tamara | - |
dc.contributor.author | López, Flora | - |
dc.contributor.author | Visa, Laura | - |
dc.contributor.author | Granja, Mónica | - |
dc.contributor.author | Martínez Lago, Nieves | - |
dc.contributor.author | Arrazubi, Virginia | - |
dc.contributor.author | Vidal Tocino, Rosario | - |
dc.contributor.author | Hernandez, Raquel | - |
dc.contributor.author | Aguado, Gemma | - |
dc.contributor.author | Cano, Juana María | - |
dc.contributor.author | Martín Carnicero, Alfonso | - |
dc.contributor.author | Mangas-Izquierdo, Montserrat | - |
dc.contributor.author | Pimentel, Paola | - |
dc.contributor.author | Fernández Montes, Ana | - |
dc.contributor.author | Macias Declara, Ismael | - |
dc.contributor.author | Longo, Federico | - |
dc.contributor.author | Ramchandani, Avinash | - |
dc.contributor.author | Martín Richard, Marta | - |
dc.contributor.author | Hurtado, Alicia | - |
dc.contributor.author | Azkarate, Aitor | - |
dc.contributor.author | Hernández Pérez, Carolina | - |
dc.contributor.author | Serrano, Raquel | - |
dc.contributor.author | Gallego, Javier | - |
dc.contributor.author | On Behalf Of The Agamenon-seom Study Group | - |
dc.date.accessioned | 2021-09-13T09:53:48Z | - |
dc.date.available | 2021-09-13T09:53:48Z | - |
dc.date.issued | 2021-01-01 | - |
dc.identifier.issn | 1758-8359 | - |
dc.identifier.uri | http://hdl.handle.net/2445/179950 | - |
dc.description.abstract | Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. Despite the lack of phase III trials, many clinicians administer trastuzumab with alternative regimens. One meta-analysis suggests that substituting cisplatin for oxaliplatin might lead to greater efficacy and less toxicity. Methods: 594 patients with HER2-positive gastroesophageal adenocarcinoma were recruited from the AGAMENON-SEOM registry. The objective was to evaluate the external validity of clinical trials with chemotherapy and trastuzumab. Results: The regimens used in at least 5% of the patients were XP (27%), oxaliplatin and capecitabine (CAPOX) (26%), oxaliplatin and 5-fluorouracil (FOLFOX) (14%), FP (14%), triplet with anthracycline/docetaxel (7%), and carboplatin-FU (5%). Median exposure to trastuzumab was longer with FOLFOX (11.4 months, 95% CI, 9.1-21.0) versus ToGA regimens (7.5, 6.4-8.5), p < 0.001. Patients with HER2-IHC 3+ cancers had higher response rates than those with IHC 2+/FISH+, odds-ratio 1.97 (95% CI, 1.25-3.09). The results achieved with CAPOX-trastuzumab were comparable to those attained with ToGA regimens. FOLFOX-trastuzumab was superior to ToGA schemes in terms of overall survival (OS), with a greater magnitude of effect in IHC 2+/FISH+ tumors (HR 0.47, 0.24-0.92) compared with IHC 3+ (HR 0.69, 0.49-0.96), and in diffuse (HR 0.37, 0.20-0.69) versus intestinal-type tumors (HR 0.76, 0.54-1.06). Conclusion: We have updated the external validity of clinical trials with trastuzumab in first-line treatment of gastric cancer. Our data confirm the comparable outcomes of ToGA regimens and CAPOX-trastuzumab in clinical practice and point toward a possible benefit of FOLFOX-trastuzumab, contingent on the subtypes typically less sensitive to trastuzumab, to be confirmed in clinical trials. | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | SAGE Publications | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1177/17588359211019672 | - |
dc.relation.ispartof | Therapeutic Advances in Medical Oncology, 2021, vol. 13, p. 175883592110196 | - |
dc.relation.uri | https://doi.org/10.1177/17588359211019672 | - |
dc.rights | cc by-nc (c) Jimenez Fonseca, Paula et al, 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Càncer d'estómac | - |
dc.subject.classification | Quimioteràpia | - |
dc.subject.other | Stomach cancer | - |
dc.subject.other | Chemotherapy | - |
dc.title | External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-09-10T10:48:41Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34211587 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
17588359211019672.pdf | 903.97 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License